Senior Pharmacist, Genomics Transformation Projects
27 July 2021
As part of NHS England’s strategy to establish a national genomics medicine service, building on the 100,000 Genomes Project, which will ensure the NHS fully benefits from advances in genomics, NHSE has commissioned 7 genomic laboratory hubs (GLHs) as part of a national network. Genomic Medicine Service Alliances (GMSA) (covering the same geography as the GLHs) will shortly be appointed to mainstream genomics. Together GLHs and GMSAs comprise the new Genomic Medicine Service which will:
- Address variations in genetic testing quality and access across the country
- Enhance the quality of information e.g. the cost and type of tests performed
- Broaden understanding of the causes of disease and the effectiveness of interventions
The GLH and GMSA covering North London, and parts of Essex and Hertfordshire, is called the North Thames. The North Thames GLH is a partnership between a number of Trusts across North London, led by Great Ormond Street NHS Foundation Trust the partners include Bart’s Health, Imperial College Hospital and its partner laboratory North West London Pathology, the Royal Marsden Hospital, UCLH NHS Foundation Trust and the Royal Free Hospital and its partner laboratory Health Services Laboratory, and the Royal National Orthopaedic Hospital.
This is a part time 0.4 WTE post at grade 8b reporting into the Chief Pharmacist, North Thames GMSA for 1 year secondment.
The main responsibilities of this role are to support the national project ‘Optimising and improving the clinical effectiveness of DPYD gene testing for patients with cancer’ on behalf of NTGMSA and to provide expert pharmacy support to the project. The objective of the project is to support the implementation and optimisation of DPYD gene testing. Key roles will include reviewing and interpreting existing data, generating new data and evidence, and working closely with multiprofessional colleagues in trusts within the NT GMSA footprint as well as nationally, to support work to embed DPYD testing equitably. There will also be opportunities to participate in other research and project work, including transformation, training and education initiatives. The postholder will also be expected to develop effective working relationships and act as an integral member of NTGMSA to support delivery of local and national project(s).
Key duties and responsibilities
- To work with pharmacy and other MDT colleagues in the NTGMSA partner organisations to co-ordinate their input on the national DPYD and other projects
- Provide expertise and input to the national DPYD working group on behalf of the NTGMSA in conjunction with the Project Lead and the GMSA pharmacy team
- To identify and prioritise pharmacy relevant milestones associated with successful delivery of the DPYD project
- Conduct baseline reviews and contribute to all elements of the national project
- Lead the mapping of pharmacy professional input into DPYD pathways to remove barriers to equitable access and develop build recommendations in accordance with the project methodology
- To be recognised as an expert within the DPYD national project representing the views of participating specialist oncology pharmacists in optimising and improving the effectiveness of DPYD gene testing for patients with cancer.
- Continue work to embed DPYD testing equitably across the region, informed by information from the national working group
- Ensure appropriate engagement and communication across NTGMSA geography and leadership teams.
- Report transformation project progress, KPI metrics and outcomes to the NTGMSA Executive Team and national project team via the Project Leads
- Support the development of a roadmap for future pharmacogenomics implementation in conjunction with the GMSA and national teams
- Support implementation and links between prescribing and genomic tests using existing digital environments including electronic prescribing and administration systems and fully integrated health records. This may typically include decision support
- Lead the mapping of pharmacy professional input into DPYD pathways to remove barriers to equitable access and develop build recommendations in accordance with the project methodology.
- Analyse prescribing and administration systems used across NTGMSA partnership trusts as part of the baseline review
- Support digital integration of DPYD testing into local prescribing systems across the GMSA, supported by outcomes of the national project
- Analyse DPYD testing data and baseline position on tests requested, tumour type, actionable results and support for implementation in accordance with the national project
- Support future developments of DPYD patient pathways through project data analysis
- Work with board patient representative groups from the Cancer Alliances to explore patient attitudes and ways to engage patients with approaches to improve the utility of DPYD testing
- Work with cancer pharmacist networks and other national specialist groups to achieve project objectives